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Optical coherence tomography (OCT) has revolutionized the field of ophthalmology since its introduction 20 years ago. Originally
intended primarily for retina specialists to image the macula, it has found its role in other subspecialties that include glaucoma,
cornea, and ocular oncology. In ocular oncology, OCT provides axial resolution to approximately 7 microns with cross-sectional
images of the retina, delivering valuable information on the eﬀects of intraocular tumors on the retinal architecture. Some
eﬀects include retinal edema, subretinal fluid, retinal atrophy, photoreceptor loss, outer retinal thinning, and retinal pigment
epithelial detachment. With more advanced technology, OCT now provides imaging deeper into the choroid using a technique
called enhanced depth imaging. This allows characterization of the thickness and reflective quality of small (<3mm thick)
choroidal lesions including choroidal nevus and melanoma. Future improvements in image resolution and depth will allow better
understanding of the mechanisms of visual loss, tumor growth, and tumor management.
1. Introduction
Since its inception in 1991, optical coherence tomography
(OCT) has found wide applications in medicine including
gastroenterology, dermatology, cardiology, and ophthalmol-
ogy [1–4]. Traditional time domain OCT, sold commer-
cially in 1995 and used primarily by retina and glaucoma
specialists, has been largely replaced by Spectral or Fourier
domain OCT that provides higher resolution images (4–
7 um) and faster scanning speeds (up to 40,000 scans
per second) that could translate to broader application of
OCT for other ophthalmic subspecialties including pediatric
ophthalmology, oculoplastics, and ocular oncology [5–8].
OCT is a valuable diagnostic tool for evaluation of
tissue architecture of the postequatorial fundus (inner
retina, outer retina, retinal pigment epithelium (RPE), and
choroid). In ocular oncology, OCT allows for diagnosis,
treatment planning, and monitoring response. Traditionally,
OCT was primarily used to image the neurosensory retina
and the retinal pigment epithelium (RPE) with outstanding
resolution, but the choroid and sclera have been poorly
imaged. Today, software upgrades and new imaging tech-
niques allow longer scan lengths, enhanced depth imaging
(EDI), and three-dimensional reconstruction. These newer
features allow demonstration of more peripheral tumors,
higher resolution images of anatomy deep to the retina,
and improved characterization of intraocular tumors [8–
10]. Herein we review clinical features of posterior segment
intraocular tumors on OCT and its applications in the
management of these lesions.
2. Choroidal Nevus
Choroidal nevi are the most common intraocular tumor.
Population studies show higher prevalence of these tumors
in Caucasians (6.5%) compared to Asians (1.4%) [11].
Nevi are typically pigmented, with smooth margins and
with overlying drusen, measuring less than 5mm in basal
diameter and 3mm in thickness. They often do not cause
visual symptoms andmore importantly are generally benign.
It has been estimated, however, that 1 in 8845 choroidal nevi
undergoes malignant transformation into melanoma [12].
Although the odds appear minimal, careful evaluation and
followup of all choroidal nevi is advised. Factors predictive
of nevus transformation into melanoma include thickness
greater than 2mm, the presence of subretinal fluid, orange
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Figure 1: Choroidal nevus. (a) Amelanotic choroidal nevus with
overlying RPE alterations and areas of RPE atrophy. (b) EDI
OCT image shows both anterior and posterior margins of the
lesion. There is gradual transition between the hyperreflective
inner choroid and hyporeflective outer choroid. There is loss of
choriocapillaris over the main lesion. Multifocal excrescences of the
RPE are also present, suggestive of drusen.
pigment, juxtapapillary location, and symptoms of blurred
vision or photopsia [13]. The presence of any one factor gives
a relative risk of 1.9, three factors 7.4, and the presence of all
five will give a relative risk of 27.1 [14].
OCT features of choroidal nevus have been extensively
documented but are limited mostly to its eﬀects on the
overlying retina and the anterior choroidal surface [8].
Shields and associates compared the frequency of retinal
findings by clinical examination to OCT [15]. They found
that OCT has a higher sensitivity than clinical examination in
detection of overlying retinal edema (15% byOCT versus 3%
by clinical examination), subretinal fluid (26% versus 16%),
retinal thinning (22% versus 0%), and RPE detachment
(12% versus 2%) [15]. OCT also enabled the examiners
to characterize retinal edema (cystoid versus noncystoid)
and determine the status of overlying photoreceptors [15].
These features are significant, since foveal edema and RPE
detachment were found to be predictive of 3 or more lines
of vision loss (RR = 22.16 and 9.02, resp.) and a final
visual outcome worse than 20/200 (RR = 12.80 and 18.72,
resp.) [16]. Overlying photoreceptor loss can also explain
associated visual field defects in some patients. Findings
localized to the RPE are also visualized readily by OCT.
OCT evidence of overlying drusen manifests as small dome-
shaped elevations at the level of the RPE/Bruch’s membrane
[15] (Figure 1). Nevus-related drusen are found in 41% of
choroidal nevi imaged by OCT and are also visualized by
ophthalmoscopy [15].
On OCT, the choroidal findings in nevi are limited to
the anterior surface and include hyporeflectivity in 62%,
isoreflectivity in 29%, and hyperreflectivity in 9% [15].
Anterior choroidal reflectivity is aﬀected by overlying RPE
alterations and the amount of pigmentation [15]. The
OCT findings reflect pigment within the mass and do not
correlate to internal reflectivity and acoustic quality by
ultrasonography, which imply density of cellularity [15].
3. Choroidal Melanoma
Uveal melanoma is the most common primary intraocular
malignancy, and 90% develop in the choroid [17]. They
often present as a pigmented, elevated, choroidal mass
with associated orange pigment and subretinal fluid. Most
choroidal melanomas can be diﬀerentiated from benign
nevi because melanoma is much larger in size. However,
approximately 30% of choroidal melanomas are small
(≤3mm thickness) and diﬃcult to diﬀerentiate from nevi
by clinical examination alone [17]. In these cases, OCT can
be helpful in the detection of melanoma-related features in
the overlying retina such as subretinal fluid [15]. Subretinal
fluid associated with melanoma shift with positioning and
may cause intermittent blurred vision or flashes. Overall,
15% and 25% of uveal melanomas metastasize in 5 and 10
years [17]. Shields and associates found subretinal fluid to
be a significant risk for metastasis in 8033 cases of uveal
melanoma, so detection of even subtle subretinal fluid by
OCT could be vital to patient prognosis [17].
Subretinal fluid is an important characteristic related
to underlying choroidal melanoma. Muscat and coworkers
studied 20 untreated choroidal melanoma and detected
subretinal fluid using time domain OCT in all cases [18].
Espinoza and colleagues also used time domain OCT to
describe an active OCT pattern, wherein a localized serous
retinal detachment was associated with an overlying retina
of normal thickness, a feature that was highly associated
with documented tumor growth (P = 0.033) and future
treatment (P = 0.014) [19]. In contrast, a chronic OCT
pattern, wherein the overlying retina was thinned, contains
intraretinal cysts and with RPE thickening was associated
with a long-standing lesion more likely to remain dormant
[19]. Sayanagi and coworkers used 3D spectral domain OCT
and found a significantly higher prevalence of subretinal
fluid (91% versus 14%), retinal edema (61% versus 14%),
and subretinal deposits (61% versus 11%) in choroidal
melanoma compared with nevi [10]. Singh and associates
used spectral domain OCT to describe dispersed accumula-
tion of subretinal deposits corresponding to orange pigment
over a small choroidal melanoma that had not been found
with time domain OCT [20]. Spectral domain OCT was also
capable of detecting early vitreous seeding as highly reflective
20–30 micron spheroidal bodies in the vitreous [21]. The
limitation of OCT for choroidal melanoma lies in the
diﬃculty of imaging the overlying retina for largemelanomas
and the inability to image past the anterior choroidal surface
[19]. Reflectivity of the anterior choroid in melanoma is
variable even with spectral domain OCT [20] (Figure 2).
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Figure 2: Choroidal melanoma. (a) Small choroidal melanoma
with overlying RPE hyperplasia and diﬀuse orange pigment accu-
mulation. (b) Spectral domain OCT clearly demonstrates subretinal
fluid that could have been missed by clinical examination alone.
Overlying the dome-shaped elevation of the choroid is a thickened
irregular RPE and thickening of the outer retinal layers.
In addition to examination of the overlying retina and
RPE, OCT has been used to monitor treatment response
and complications following radiotherapy for choroidal
melanoma. Horgan and associates performed pre- and
postplaque radiotherapy OCT and found that the mean time
to onset of radiation maculopathy was 12 months [22]. The
authors also reported that 17% had macular edema by OCT
at 6 months, 40% at 12 months, and 61% at 24 months
[22]. In comparison, radiation maculopathy was detected
by clinical examination alone 1% by 6 months, 12% at 12
months, and 29% at 24 months [22]. Further, OCT enabled
the authors to classify macular edema into extrafoveolar
noncystoid (grade 1), extrafoveolar cystoid (grade 2), fove-
olar noncystoid (grade 3), mild-moderate foveolar cystoid
(grade 4), and severe foveolar cystoid (grade 5) [22]. This
qualitative classification correlated with quantification of
central foveolar thickness. In such cases, both OCT and
visual acuity can be used to monitor treatment response
following laser photocoagulation, intravitreal anti-VEGF,
and intravitreal triamcinolone for radiation macular edema.
4. Choroidal Metastasis
The choroid is the most common site of metastasis in the
eye because of its vascularity. Patients usually present with
painless blurring of vision, and 66% will have a prior history
of systemic cancer, most commonly the breast in women and
the lungs in men [23]. Among the 34% without a history of
systemic cancer, the lung is the most common primary site
(a)
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Figure 3: Choroidal metastasis. (a) Amelanotic choroidal metas-
tasis in a patient with breast cancer. (b) EDI OCT reveals both
the anterior and posterior margins of the metastasis allowing
measurement of tumor thickness and characterization of its internal
structure. Multiple nodular elevations of the RPE can also be
seen with thickening of the RPE, overlying subretinal fluid,
and hyperreflective deposits within the neurosensory detachments
presumably from tumor cells or macrophages.
after workup [23]. Clinically, choroidal metastasis appears
as a solitary, nonpigmented choroidal mass with associated
shifting subretinal fluid [23]. They can occasionally be
associated with overlying RPE alterations and brown
pigment accumulation corresponding to lipofuscin.
OCT of choroidal metastasis demonstrates a dome-
shaped elevation of the neurosensory retina and RPE with
adjacent subretinal fluid (Figure 3). It can also be associated
with retinal edema, intraretinal cysts, and thickening and
detachment of the RPE. Natesh and associates found highly
reflective subretinal deposits corresponding to RPE clumping
overlying the tumor on clinical examination [24]. Arevalo
and colleagues also found highly reflective points within
neurosensory detachment in 14.2% of cases and concluded
that these points “may correspond to retinal compromise
by cancer cells or macrophages containing lipofuscin and
melanin granules” [25]. Choroidal features are also limited
to the anterior surface as with all choroidal tumors, and
they often have variable reflectivity [10]. In addition to
its diagnostic capabilities, OCT is valuable in monitoring
treatment response, since resolution of subretinal fluid and
return of normal retinal architecture has been documented
following therapy [25, 26].
5. Choroidal Hemangioma
Choroidal hemangiomas are benign vascular tumors that
are either circumscribed or diﬀuse based on the extent
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of choroidal involvement [27]. Circumscribed choroidal
hemangioma is usually orange colored, round, located in
the posterior pole, and exhibits overlying retinal edema,
subretinal fluid, and RPE alterations [28]. Choroidal heman-
gioma shows high internal reflectivity and acoustic solidity
on ultrasonography, while often demonstrating a bright early
filling and a characteristic late “wash out” on indocyanine
green angiography [28]. On MRI, it is hyperintense to
vitreous on T1, and isointense on T2, unlikemost intraocular
tumors, which are hypointense on T2 [28]. The diﬀuse
variant usually extends to involve the entire choroid and
is often associated with an ipsilateral facial hemangioma
(nevus flammeus) that together comprise the Sturge-Weber
syndrome [27, 28].
Ramasubramanian and colleagues described OCT find-
ings in circumscribed choroidal hemangioma and found
subretinal fluid (19%), retinal edema (42%), retinal schisis
(12%), macular edema (24%), and localized photoreceptor
loss (35%) [29]. The same group also described OCT
findings in diﬀuse choroidal hemangioma and reported sub-
retinal fluid (28%), retinal edema (14%), and photoreceptor
loss (43%) [29]. Acute leakage from choroidal hemangioma
demonstrates subretinal fluid with preserved photoreceptor
layer and normal retinal thickness, whereas chronic leakage
displays loss of photoreceptors, retinoschisis, and intraretinal
edema associated with subretinal fluid [8] (Figure 4). By
OCT, the anterior tumor surface is hyporeflective [10].
Currently, OCT has been used to monitor response to
treatment by photodynamic therapy, transpupillary ther-
motherapy, plaque radiation, or laser photocoagulation.
Blasi and associates performed photodynamic therapy on 25
cases of circumscribed choroidal hemangioma and reported
a decrease in central foveal thickness and restoration of foveal
anatomy following treatment after 5 years [30].
6. Choroidal Osteoma
Choroidal osteoma is a rare, osseous tumor often found
in young females. This tumor appears as an orange-yellow
plaque in the juxtapapillary region or macula but can
demonstrate areas of whitening when decalcified. This tumor
is benign but has the capacity to grow. Long-term studies
have shown growth rates of 41–51%, choroidal neovascu-
larization in 31–47%, and final visual outcome worse than
20/200 in 56–58% after 10 years [31, 32]. The mechanisms
of visual loss include subretinal fluid, choroidal neovascu-
larization, and photoreceptor loss. Shields and colleagues
followed 74 eyes with choroidal osteoma to find subretinal
fluid and tumor decalcification as factors predictive of poor
visual outcome or loss of 3 or more lines of vision [32].
The internal structure of choroidal osteoma is diﬃcult to
evaluate with OCT and is limited to its anterior surface [8].
The overlying inner retina is often preserved while changes
in the outer retinal layers, namely, the photoreceptors and
the RPE, are often observed [8]. The RPE can sometimes be
continuous with the inner surface of the underlying tumor,
and the degree of calcification aﬀects the amount of light
transmission [8, 33, 34] (Figure 5). Shields and coworkers
reported on the OCT features of choroidal osteoma and
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Figure 4: Choroidal hemangioma. (a) Choroidal hemangioma
along inferotemporal arcade with subtle exudation seen inferonasal
and inferotemporal to the foveola. (b) Time domain OCT shows
dome-shaped elevation of its posterior border with overlying
retinoschisis and retinal edema.
reported heterogeneity that largely depends on the amount
of calcification [35]. Calcified portions of the tumor reveal
mostly intact inner (100%) and outer (95%) retinal layers, a
distinct RPE (57%), and mild transmission of light (95%)
[35]. In contrast, decalcified portions of the tumor reveal
intact inner retinal layers (90%), thinned outer retinal
layers (100%), an indistinct RPE (90%), and marked light
transmission into the tumor (70%) [35]. They also described
focal areas of shadowing behind areas of RPE hyperplasia
[35]. The anterior tumor surface was hyperreflective in
48% and isoreflective in 52% if calcified but was mostly
hyperreflective (90%) when decalcified [35].
7. Lymphoid Tumors
Intraocular lymphoid tumors can occur in diﬀerent parts
of the eye with varying prognostic implications. There are
two basic types, the vitreoretinal type and the uveal type.
Vitreoretinal lymphoma accounts for most cases and are
primarily diﬀuse large b-cell lymphomas [36]. They are
aggressive tumors, highly associated with central nervous
system lymphomas [36]. Patients are often elderly and
immunocompetent or young and immunocompromised.
Clinically, they present as bilateral multifocal yellowish
deposits in the retina, subretina, or sub-RPE with overlying
vitreous opacities. Pigmentmigration and RPE clumping can
sometimes be visible overlying the tumor as brown leopard
spots.
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Figure 5: Choroidal osteoma. (a) Decalcified circumpapillary
choroidal osteoma with associated pigment migration and RPE
atrophy. (b) EDI OCT demonstrates replacement of the normal
choriocapillaris with a dense hyperreflective mass with a scalloped
posterior border and an adjacent hyporeflective space anterior to
the sclera. The main lesion is almost continuous with the overlying
RPE. Overlying neurosensory retina is thinned with the loss of the
outer layers.
Uveal lymphoid tumors involve the choroid, ciliary
body, and iris, often with conjunctival and orbital compo-
nents. Most are extranodal marginal zone b-cell lymphoma
although a benign reactive lymphoid hyperplasia subtype
exists that presents similarly albeit less aggressive [36].
Choroidal lymphoid tumors are usually unilateral. They
present as multifocal orange-yellow choroidal infiltrates
resembling those from white dot syndromes [36]. In time,
they can involve the entire uveal tract causing a diﬀuse
thickening of the uvea on ultrasonography often with a small
round echolucency behind the sclera [37]. The overlying
retina and vitreous remain clear; however, the fornix or
conjunctiva can be involved as “salmon patches” [36].
Compared to vitreoretinal lymphoma, uveal lymphomas are
more indolent, but an association with systemic lymphoma
exists.
Diagnosis of all intraocular lymphoid tumors should be
done with a biopsy, either from an associated conjunctival or
forniceal involvement or through vitrectomy and fine needle
biopsy of the involved ocular tissue. Ancillary testing is not
absolutely necessary although it can provide insight on the
extent of involvement. OCT in vitreoretinal lymphomas may
show dome-shaped elevations of the RPE or small nodular
RPE irregularities from sub-RPE tumor deposits, retinal
elevation or thickening from tumor infiltration, and cystoid
macular edema from associated inflammatory reaction [38–
40] (Figure 6). Fardeau and associates examined 61 eyes with
vitreoretinal lymphoma confirmed through vitreous biopsies
and found that 41.7% had nodular elevations of the RPE
[40]. The authors also reported a significantly thinner central
foveal thickness compared to eyes with posterior uveitis
other than lymphoma [40]. OCT performed in choroidal
lymphoma shows regular intermittent placoid choroidal
thickening and loss of choriocapillaris [41]. The overlying
RPE and neurosensory retina is unaﬀected and retains its
regular, smooth contour [41].
8. Congenital Hypertrophy of the Retinal
Pigment Epithelium
Congenital hypertrophy of the retinal pigment epithelium
(CHRPE) is a benign, flat, and pigmented lesion rarely
associated with vision loss or visual field defects. This tumor
is often unilateral and solitary but can occasionally be
multifocal or grouped in a bear-track distribution. Familial
adenomatous polyposis and Gardner’s syndrome have been
associated with a variant, wherein lesions appear in a
haphazard multifocal distribution, and individual CHRPE
has irregular borders and an atrophic “tail.” Shields and
coworkers reported atrophic lacunae in 43% occupying a
median 5% of the total area [42]. In their series of 330
patients with 337 lesions, growth in basal dimensions was
documented by photographic comparison in 46%, while
5 (1.4%) lesions had a nodular elevation within CHRPE
[42].
OCT imaging of CHRPE can be diﬃcult due to its
peripheral location but could potentially be better captured
using longer scan lengths by new-generation spectral domain
OCT. Shields and colleagues described overlying retinal thin-
ning and photoreceptor loss in all patients with CHRPE that
likely account for visual field defects [43]. The neurosensory
retina overlying CHRPE was only 68% the thickness of
adjacent normal retina [43]. Pigmented CHRPE has 52%
thicker RPE than adjacent normal retina that prevents light
transmission and shadows the underlying choroid [43].
Nonpigmented CHRPE, on the other hand, has large areas
of lacunae with thinner RPE that allow transmission of light
and partial visualization of the choroid [43] (Figure 7).
9. Combined Hamartoma of the Retina and
Retinal Pigment Epithelium
A typical appearance of combined hamartoma of the retina
and RPE is an elevated grey mass of the retina blending
imperceptibly with surrounding retina and RPE without
retinal detachment, or vitreous inflammation. There is often
an associated preretinal fibrosis with traction on the adjacent
retina. In a classic report by Schachat and associates from
the Macula Society, vascular tortuosity was present in 93%,
vitreoretinal surface abnormalities in 78%, pigmentation in
87%, and associated lipid exudation in 7% [44]. Shields
and coworkers analyzed 77 cases based on macular versus
extramacular location and reported more visual acuity loss
≥3 Snellen lines in the macular group (60% versus 13%)
[45].
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Figure 6: Vitreoretinal lymphoma. (a, b) Bilateral vitreoretinal lymphoma with multifocal cream-colored subretinal infiltrates. (c) Time
domain OCT of the right eye reveals multiple nodular elevations of the RPE from deposits in the sub-RPE space. (d) Time domain OCT of
the left eye shows multiple dome-shaped elevations of the RPE from more extensive infiltrates and subretinal fluid.
(a)
(b)
Figure 7: Congenital hypertrophy of the retinal pigment epithelium
(CHRPE). (a) Large, peripheral CHRPE with centrally located
lacunae. (b) Time domain OCT shows thinning of the overlying
retina and loss of photoreceptors, posterior shadowing of the
choroid in pigmented regions and light transmission to the under-
lying choroid in scans along lacunae.
Shields and colleagues described time domain OCT
features in 11 cases of combined hamartoma of the retina
and RPE, reporting anatomic disorganization with loss of
identifiable retinal layers in all cases [46] (Figure 8). OCT
evidence of epiretinal membrane was found in 91%, and
mean retinal thickness was 766 um [46]. In their series,
OCT images showed intact RPE in cases without signifi-
cant posterior shadowing. Spectral domain OCT has been
reported recently but did not add significant information to
traditional time domain OCT [47].
10. Retinoblastoma
Retinoblastoma is the most common primary intraocular
tumor in children. What used to be a malignancy with
a dismal survival rate now has the highest cure rate in
developed countries with the introduction of chemoreduc-
tion [48]. Retinoblastoma appears as a yellow-white retinal
mass with feeding vessels when entirely intraretinal. When
exhibiting an endophytic growth pattern, it is characterized
by overlying vitreous seeds. Exophytic retinoblastoma, on the
other hand, is associated with serous retinal detachment and
occasional subretinal seeds. A rare diﬀuse pattern of growth
is characterized by horizontal rather than vertical growth and
can masquerade as uveitis [49].
Individual retinoblastoma tumors appear on OCT as
thickening and disorganization of the neurosensory retina
with posterior shadowing possibly from inherent calcifica-
tion [5] (Figure 9). Associated subretinal fluid or intraretinal
cysts are clearly visualized on OCT when present [5, 50]. The
role of OCT lies in its ability to image themacula, particularly
the fovea. This is important in children with retinoblastoma,
since restoration of normal foveal anatomy may be achieved
following treatment [51]. Further, diﬀerentiation from an
organic (i.e., macular edema and loss of photoreceptors)
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Figure 8: Combined hamartoma of the retina and RPE. (a)Macular
combined hamartoma of the retina and RPE with dense preretinal
fibrosis at its nasal border. (b) EDI OCT demonstrates gradual
transition from the normal adjacent inner retinal layers to a
disorganized mass with an overlying tuft of preretinal fibrosis. The
outer plexiform layer, external limiting membrane, photoreceptor
inner segment-outer segment junction, the RPE, and underlying
choroid are intact.
versus a nonorganic (i.e., amblyopia) cause of vision loss
is essential to plan for long-term visual rehabilitation and
maximizing outcome in all patients.
OCT images of retinoblastoma are diﬃcult to obtain
because traditional OCT imaging needs a certain degree
of cooperation that is diﬃcult to expect from children.
This inherent limitation of OCT machines made reports
on OCT of retinoblastoma few and lacking. Today, the
development of handheld OCT has revolutionized intraop-
erative imaging capabilities that could have a tremendous
impact on managing childhood ocular diseases such as
retinopathy of prematurity and retinoblastoma [52]. These
can deliver high-resolution spectral domain OCT images
with 3D reconstruction capabilities [52].
11. Retinal Astrocytic Hamartoma
Retinal astrocytic hamartoma (astrocytoma) is a benign,
vascularized, and glial tumor of the retina that may be
acquired or congenital. Acquired astrocytic hamartomas
appear as yellow-white mass of the inner retina that may
be associated with adjacent retinal traction, cystoid macular
edema, exudation, and nondilated feeder vessels. They gen-
erally lack calcification compared with the congenital form
but are otherwise similar ophthalmoscopically. Congenital
astrocytic hamartomas present in younger patients, may
acquire intrinsic calcification through time, and are some-
times associated with central nervous system astrocytomas
(a)
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Figure 9: Retinoblastoma. (a) Mostly calcified retinoblastoma
following chemoreduction and consolidation. (b) Time domain
OCT demonstrates disorganization and irregularity of the inner
retinal layers and posterior shadowing from calcification.
in the tuberous sclerosis complex. Both forms often do
not require treatment but may at times exhibit progressive
growth that leads to blindness and eye pain from neovascular
glaucoma that require enucleation [53].
Astrocytic hamartomas show inner retinal thickening
and disorganization with a gradual transition to the adja-
cent normal retina [5, 54] (Figure 10). Calcified tumors
have higher reflectivity and greater posterior shadowing,
while noncalcified tumors allow some light transmission to
demonstrate intact outer retinal layers [54, 55]. There may
be associated retinal traction in 27%, an intrinsic moth-eaten
appearance from intratumoral cysts in 67%, and adjacent
retinal or macular edema in 47% [54]. When treatment is
initiated for macular edema, OCT may be used to follow
resolution of subretinal fluid or release of macular traction
[56, 57]. High-resolution spectral domain OCT confirms
the intact outer retinal structures, as well as the underlying
choriocapillaris [58]. 3D reconstruction demonstrates tumor
architecture and its relationship to the adjacent retina in a
single image [58].
12. Retinal Cavernous Hemangioma
Cavernous hemangioma is a benign retinal vascular tumor
that appears as dark-red saccular aneurysms. This tumor
can be associated with overlying preretinal fibrosis, vitreous
hemorrhage, or vascular occlusion [28, 59]. Retinal exuda-
tion and edema are typically not associated [28]. There is a
familial tendency from mutation of the cerebral cavernous
malformation gene located in chromosome 7 in which
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Figure 10: Retinal astrocytic hamartoma. (a) Juxtapapillary retinal
astrocytic hamartoma with preretinal fibrosis and nasal dragging of
the macula. (b) Spectral domain OCT image exhibits disorganiza-
tion of the inner retinal layers and an intact RPE underlying the
tumor. There is posterior shadowing presumably from calcification
of the tumor apex. A dense epiretinal membrane causes the traction
of the adjacent normal retina.
cerebral or cutaneous cavernous hemangiomas may also be
present [8, 28].
Features of cavernous hemangioma on OCT include
lobulated, hyperreflective masses in the inner retina that
correspond to the aneurysms. Optically clear cystic spaces
may be present within the main hyperreflective mass [8, 60]
(Figure 11). A preretinal membrane with traction on the
adjacent retina may also be found; subretinal fluid is typically
absent.
13. Retinal Hemangioblastoma
Retinal hemangioblastoma (capillary hemangioma) is an
orange-red circumscribed vascular lesion with dilated feed-
ing artery and draining vein. When multifocal, bilateral, or
occurring in children less than 10 years, they are more often
associated with von Hippel-Lindau disease [61]. This tumor
can be associated with adjacent retinal exudation or remote
cystoid macular edema. Advanced cases may have extensive
serous retinal detachment, or neovascular glaucoma [28].
On OCT, retinal hemangioblastoma appears as an opti-
cally dense inner retinal mass with posterior shadowing
due to intrinsic diﬀuse capillary channels [5, 8] (Figure 12).
OCT is used mostly for the detection of macular edema,
epiretinal membrane, and subretinal fluid associated with
retinal hemangioblastoma [5, 8]. It is particularly useful for
monitoring response to treatment.
(a)
(b)
Figure 11: Retinal cavernous hemangioma. (a) Cavernous heman-
gioma along the superotemporal arcade with associated preretinal
fibrosis. Note similar lesions over the optic disc. (b) Time domain
OCT shows a lobulated inner retina with optically clear spaces
representing the saccular aneurysms. The underlying RPE is intact.
14. Retinal Vasoproliferative Tumor
The vasoproliferative tumor of the ocular fundus is usually
a unilateral, solitary, and yellow-red retinal lesion located
in the inferotemporal periphery with minimally dilated or
nondilated feeding artery and draining vein in contrast to
hemangioblastoma. Most cases are primary, but 26% are
secondary and associated with retinitis pigmentosa, pars
planitis, and posterior uveitis, among others [62]. They
may have associated macular edema, epiretinal membrane,
exudative retinal detachment, or vitreous hemorrhage.
Inner retinal layer disorganization and posterior shad-
owing are features of vasoproliferative tumors on OCT [63]
(Figure 13). They are diﬃcult to image with OCT due to
their peripheral location, but newer machines with longer
scan lengths may be useful. OCT is beneficial for detecting
associated preretinal fibrosis, macular edema, and subretinal
fluid, as well as monitoring treatment [64].
15. Enhanced Depth Imaging Optical
Coherence Tomography
Choroidal visualization has been rendered easier and more
precise than before thanks to enhanced depth imaging (EDI)
spectral domain OCT. The diﬃculty faced with conventional
spectral domain OCT in imaging the choroid includes
decreasing resolution and sensitivity with increasing depth
beyond the retina, wavelength-dependent light scattering by
RPE and choroid, and the limited 40 decibel dynamic range
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Figure 12: Hemangioblastoma. (a) Optic disc hemangioblastoma
with a faint epiretinal membrane along the nasal edge of the fovea.
(b) EDI OCT demonstrates a dome-shaped elevation of the inner
retina with abrupt transition to the adjacent normal tissue and
complete shadowing of the posterior layers. The adjacent RPE and
choriocapillaris are intact.
inherent in Fourier domain systems. In EDI, the instrument
is displaced to image deeper layers, and an inverted image
is obtained with the superficial layers imaged at the bottom
and the deeper layers imaged at the top. This image when
flipped is comparable to the conventional spectral domain
OCT image but with the choroid and inner sclera visualized
at a higher resolution and sensitivity [65]. EDI OCT features
have been described in normal choroid, age-related macular
degeneration, and myopia [66–68]. This technique can be
valuable for studying the structure and extent of choroidal
tumors. A small pilot study suggested that small choroidal
tumors (<1.0mm in thickness and <9.0mm in diameter),
that are not detectable by ultrasonography, can be objectively
measured by this technique [69]. Notably, even with high-
quality choroidal images obtained, the retinal image quality
is not compromised. In this preliminary study, EDI OCT
showed promise in its ability to measure tumor thickness
and visualizing internal structure. Its role in ocular oncology
is hopeful, but further studies are still needed to better
understand its histopathologic correlation.
16. Swept Source Imaging Optical
Coherence Tomography
On the horizon is even higher-grade technology with “swept
source” imaging. This employs a long wavelength light source
that, at each point, a wavelength of light is rapidly swept
across a band of wavelengths with a resultant signal detected
by a sensitive photodiode. The photodiode is more sensitive
(a)
(b)
Figure 13: Vasoproliferative tumor. (a) Vasoproliferative tumor
located at inferior periphery with preretinal fibrosis at its superior
border and yellow subretinal fibrosis nasally. (b) Time domain
OCT reveals a hyperreflective and disorganized inner retina with
shadowing of the posterior layers including the RPE. An epiretinal
membrane is seen at its posterior border.
and quicker than the charge-coupled devices (CCDs) used in
spectral domain OCT. This extremely fast scan can produce
101,000 A scans per second. Imaging of both the retina and
choroid is excellent with good deep penetration into the
choroid due to the longer wavelength.
17. Conclusion
Conventional OCT is a valuable tool to visualize anatomic
alterations induced by retinal and choroidal tumors. Newer
OCT methods with EDI and swept source OCT can allow in
vivo cross-sectional imaging of choroidal tumors with details
on the tumor structure and measurement of tumor thickness
too thin for measurement by ultrasonography.
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